SIRION Biotech GmbH: SIRION Biotech Announces Collaboration with Sanofi to Innovate Gene Therapy Treatments with Improved Adeno-Associated Virus Capsids
(2) Joining forces to develop gene therapies for multiple life-threatening disorders SIRION Biotech GmbH, a world leader in viral vector-based gene delivery technologies for gene cell therapy, announced today that it signed a license and collaboration agreement with Sanofi, a global biopharmaceutical company, to develop improved tissue-selective adeno-associated virus (AAV) vectors to realize effective gene therapy treatments for disorders affecting major human organs. AAV vectors are a promising and clinically validated gene delivery platform for the potential treatment of a variety of h...